semaglutide cagrilintide Subcutaneous Cagrilintide, Shows Significant Weight Loss in Type 2 Diabetes Trial CagriSema vs Tirzepatide: 23% Weight
Description
The significant reduction in the risk of MAKEs observed in our study could be attributed to the relatively longer follow-up period and the larger number of participants
They provide an estimate of equivocal dosages to minimize the risk of underdosing or overdose, maximize efficacy, and reduce GI side effects
When Should You Seek Medical Advice
Over 3 to 6 months of consistent GLP-1 medication use with appropriate dietary support, many people find that their gut microbiome adapts to the new digestive environment
SOURCE: JAMA Ophthalmology , Feb
